Biotech/Pharma Stocks to Watch; (BPAX, RXII, DNDN, CPRX)
POINT ROBERTS - September 13, 2001 - www.InvestorIdeas.com, a global investor research portal for independent investors issues a report for biotech and pharma stocks to watch based on trading and news for 12th September.
U.S. markets ended higher after falling sharply earlier in the trading session boosted by some reports that China could rescue European debt markets. Bitotechnology stocks were among the top per performers with the NASDAQ Biotechnology Index climbing 6.6 or 0.71% to $982.57, near the day's high of 982.84.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) shares ended higher by 0.73% to $2.77 after hitting a day's high of $2.90. On Monday, the company announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free testosterone, bioavailable testosterone and total testosterone in the serum of postmenopausal women to within the normal ranges for younger, premenopausal women.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) was one of the top biggest gainers and moved 14 cents or 14% to $1.14, off day's high of $1.28. The company announced that the FDA has expanded a partial clinical hold on the company's NeuVax, which had been earlier delaying a late-stage study.
Dendreon Corporation (NASDAQ:DNDN) shares rose 29 cents or 2.54% to $11.69, recovering from day's low of $10.89. Analyst at Roth Capital has downgraded the stock to Neutral from Buy. Also, an analyst at ThinkEquity reduced its price target on the stock to $21 with a buy rating.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) jumped 17 cents or 13.46% to close at day's high of $1.45. More than 70.5K shares traded hands, compared to its average volume 31.13K shares. The stock moved following an article from Seekingalpha, which listed the stock as a top ceap biotech stocks that could double or triple by next year.
Research more biotech stocks at the Biotech stocks Directory:http://www.investorideas.com/BIS/Stock_List.asp
Showcase Biotech/Pharma stock at Investorideas.com:
BioSante Pharmaceuticals, Inc.
http://www.biosantepharma.com/
Read the August 2011 Fact Sheet in Full
http://www.biosantepharma.com/downloads/BioSante-Fact-Sheet.pdf
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
312-506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
http://www.investorideas.com/CO/BPAX/
Request news, updates and trading alerts on BPAX http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: The following investor idea and featured is a not a recommendation, but a profile of one of many publicly traded biotech and pharma stocks for investors to research. Disclosure: BPAX is a featured showcase stock and compensates Investorideas.com (six thousand five hundred for three months advertising) our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites
www.InvestorIdeas.com/About/Disclaimer.asp
Contact Investorideas.com
800-665-0411 - dawn@investorideas.com or cvanzant@investorideas.com
Source - Investorideas.com
Tuesday, September 13, 2011
Monday's NASDAQ
Winners: GLBL. NETL, NTSP, EZCH
POINT ROBERTS - September 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday September 12th. NASDAQ closed up at the end of the trading session at 2,495.09 +27.10 +1.10%. Merger news created the top two gainers for the day.
Global Industries, Ltd. (NasdaqGS: GLBL) was the top percentage gainer for the day closing up at $7.78, with an impressive gain of $ 2.63 (51.07%). The company announced that it entered into a definitive merger agreement with Technip (NYSE Euronext Paris: TEC) under which Technip will acquire Global in an all cash merger. Under the terms of the agreement, which was unanimously approved by Global's Board ofDirectors , Global stockholders will receive $8.00 in cash for each share of Global's common stock. The transaction values Global at an enterprise value of approximately $1,073 million, including Global's approximately $136 million of net debt. The $8.00 per share acquisition price represents a 55% premium to Global's closing share price on September 9, 2011, the last trading day prior to announcement of the transaction, and a 92% premium to Global's average closing share price for the 30 trading days ending on September 9, 2011.
NetLogic Microsystems, Inc. (NasdaqGS: NETL) ran a close second, with a gain of 50.80%, closing at $48.12, up $16.21. Another big deal maker for the market, Broadcom Corporation (Nasdaq:BRCM), and NetLogic Microsystems, Inc. (Nasdaq:NETL) announced they have entered into a definitive merger agreement. Under the agreement, NetLogic Microsystems shareholders will receive $50 per share in a transaction of approximately $3.7 billion, net of cash assumed.
NetSpend Holdings, Inc. (NasdaqGS: NTSP) closed up at $5.74, up 0.60 (11.67%). The company is a provider of general-purpose reloadable (GPR) prepaid debit cards and related financial services to the estimated 60 million underbanked consumers in the UnitedStates who do not have a traditional bank account or who rely on alternative financial services.
EZchip Semiconductor Limited (NasdaqGS: EZCH) ended at $32.65, up 3.25 (11.05%) and continued its run in after hours trading. The stock was one of several semiconductor stocks that had gains following the NetLogic / Broadcom deal news.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
POINT ROBERTS - September 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday September 12th. NASDAQ closed up at the end of the trading session at 2,495.09 +27.10 +1.10%. Merger news created the top two gainers for the day.
Global Industries, Ltd. (NasdaqGS: GLBL) was the top percentage gainer for the day closing up at $7.78, with an impressive gain of $ 2.63 (51.07%). The company announced that it entered into a definitive merger agreement with Technip (NYSE Euronext Paris: TEC) under which Technip will acquire Global in an all cash merger. Under the terms of the agreement, which was unanimously approved by Global's Board of
NetLogic Microsystems, Inc. (NasdaqGS: NETL) ran a close second, with a gain of 50.80%, closing at $48.12, up $16.21. Another big deal maker for the market, Broadcom Corporation (Nasdaq:BRCM), and NetLogic Microsystems, Inc. (Nasdaq:NETL) announced they have entered into a definitive merger agreement. Under the agreement, NetLogic Microsystems shareholders will receive $50 per share in a transaction of approximately $3.7 billion, net of cash assumed.
NetSpend Holdings, Inc. (NasdaqGS: NTSP) closed up at $5.74, up 0.60 (11.67%). The company is a provider of general-purpose reloadable (GPR) prepaid debit cards and related financial services to the estimated 60 million underbanked consumers in the United
EZchip Semiconductor Limited (NasdaqGS: EZCH) ended at $32.65, up 3.25 (11.05%) and continued its run in after hours trading. The stock was one of several semiconductor stocks that had gains following the NetLogic / Broadcom deal news.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Source - www.Investorideas.com
Monday's TSX Gold Stocks Trading Snapshot; VGZ, PLG, ORE, GBB, YLL
POINT ROBERTS - September 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, including gold and mining stocks reports on TSX gold stocks trading for Monday September 12th. Gold closed up at $1,826.50 +16.60 +0.92%.
Vista Gold Corporation (VGZ.TO) was the top percentage gainers, closing at $4.37, up 0.69 (18.75%). The company announced last week the results of a new mineral resource estimate for the Batman deposit at the Company's Mt. Todd gold project in Northern Territory, Australia. The new mineral resource estimate includes all previous drilling information plus the results from the 2010-2011 drilling program, which were previously announced by the Company on June 27, 2011. The total mineral resource estimate for the Batman deposit is now 5.98 million ounces of measured and indicated mineral resources) and 2.61 million ounces of inferred mineral resources.
Gold Bullion Development Corporation (GBB.V) closed at 0.345, down 0.01 (2.82%). The company recently reported in late August that it has completed 6,842 m in 12 holes of diamond drilling in its first drill campaign on the Castle Silver property historic past-producing silver mine property located 85 kilometres northwest of the historic silver camp in Cobalt, Ontario.
PILOT GOLD INC (PLG.TO) closed at $2.31, up 0.13 (5.96%). The company reported last week, a new bulk tonnage style gold discovery in northeastern Elko County, Nevada. The first five holes ever drilled on the Company's 100% owned Viper Project have intersected widespread, sediment hosted, oxide gold and silver mineralization starting at surface.
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB) closed at $0.045.
In a recent interview, Ian Foreman, President, noted “Yale has 9 projects in Mexico. We concentrate in northwestern Mexico in the mining friendly jurisdictions of Sonora and Chihuahua. We have gold, silver and base metal projects and we currently have four projects optioned out. I am always working to add to that and am confident that we will have an additional two properties optioned out before the end of the year.
It is going to be a very busy fall/winter for us as many projects will be worked on and we anticipate that we’ll have a couple of our properties drilled as well.”
Orezone Gold Corporation (ORE.TO) closed up at $ 3.75, up 0.18 (5.04%)
The company announced additional positive drill results from an ongoing 170,000 m infill and expansion drill program at its 100% owned Bombore Gold Project in Burkina Faso, West Africa. Results include 234 reverse circulation (RC) holes (11,942 m) and 43 core holes (6,979 m) from the northern and southern portions of the 11 km long Bombore resource.
Featured Gold Stocks:
Learn more about our gold stocks at
http://www.investorideas.com/Gold_Stocks/
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Visit the profile page on Investorideas.com
http://www.investorideas.com/ CO/YLL/
Gold Bullion Development Corporation (GBB.V)
Visit the profile page on Investorideas.com
http://www.investorideas.com/ CO/GBB/
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts! http://www.investorideas.com/Resources/Newsletter.asp
How to research and trade gold stocks: the investor ideas mining stock directory has over 1400 publicly traded mining stocks:
http://www.investorideas.com/ Gold_Stocks/Stocks_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com has been compensated by mining stocks YLL, GBB averaging five hundred per month as a showcase stock or paid news releases.
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Contact us http://www.investorideas.com/About/Contact.asp
Source - Investorideas.com
POINT ROBERTS - September 13, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, including gold and mining stocks reports on TSX gold stocks trading for Monday September 12th. Gold closed up at $1,826.50 +16.60 +0.92%.
Vista Gold Corporation (VGZ.TO) was the top percentage gainers, closing at $4.37, up 0.69 (18.75%). The company announced last week the results of a new mineral resource estimate for the Batman deposit at the Company's Mt. Todd gold project in Northern Territory, Australia. The new mineral resource estimate includes all previous drilling information plus the results from the 2010-2011 drilling program, which were previously announced by the Company on June 27, 2011. The total mineral resource estimate for the Batman deposit is now 5.98 million ounces of measured and indicated mineral resources) and 2.61 million ounces of inferred mineral resources.
Gold Bullion Development Corporation (GBB.V) closed at 0.345, down 0.01 (2.82%). The company recently reported in late August that it has completed 6,842 m in 12 holes of diamond drilling in its first drill campaign on the Castle Silver property historic past-producing silver mine property located 85 kilometres northwest of the historic silver camp in Cobalt, Ontario.
PILOT GOLD INC (PLG.TO) closed at $2.31, up 0.13 (5.96%). The company reported last week, a new bulk tonnage style gold discovery in northeastern Elko County, Nevada. The first five holes ever drilled on the Company's 100% owned Viper Project have intersected widespread, sediment hosted, oxide gold and silver mineralization starting at surface.
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB) closed at $0.045.
In a recent interview, Ian Foreman, President, noted “Yale has 9 projects in Mexico. We concentrate in northwestern Mexico in the mining friendly jurisdictions of Sonora and Chihuahua. We have gold, silver and base metal projects and we currently have four projects optioned out. I am always working to add to that and am confident that we will have an additional two properties optioned out before the end of the year.
It is going to be a very busy fall/winter for us as many projects will be worked on and we anticipate that we’ll have a couple of our properties drilled as well.”
Orezone Gold Corporation (ORE.TO) closed up at $ 3.75, up 0.18 (5.04%)
The company announced additional positive drill results from an ongoing 170,000 m infill and expansion drill program at its 100% owned Bombore Gold Project in Burkina Faso, West Africa. Results include 234 reverse circulation (RC) holes (11,942 m) and 43 core holes (6,979 m) from the northern and southern portions of the 11 km long Bombore resource.
Featured Gold Stocks:
Learn more about our gold stocks at
http://www.investorideas.com/Gold_Stocks/
Yale Resources Ltd. (TSX-V - YLL and Frankfurt - YAB)
Visit the profile page on Investorideas.com
http://www.investorideas.com/ CO/YLL/
Gold Bullion Development Corporation (GBB.V)
Visit the profile page on Investorideas.com
http://www.investorideas.com/ CO/GBB/
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts! http://www.investorideas.com/Resources/Newsletter.asp
How to research and trade gold stocks: the investor ideas mining stock directory has over 1400 publicly traded mining stocks:
http://www.investorideas.com/ Gold_Stocks/Stocks_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com has been compensated by mining stocks YLL, GBB averaging five hundred per month as a showcase stock or paid news releases.
www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411
Contact us http://www.investorideas.com/About/Contact.asp
Source - Investorideas.com
Monday, September 12, 2011
Small Cap Wind Stocks to Watch: (OTC: WWPW), (OTC: CWET), (CYW.F, CYW.DE)
PointRoberts , WA - September 12, 2011 - Investorideas.com, a leader in cleantech stock research, reports on Small cap wind stocks trading and recently issued news and updates for investors following the renewable energy sector.
City Windmills, Ltd. (Frankfurt : CYW.F, CYW.DE) announced today that Silvia Quandt & Cie, a leading German investment banking and brokerage firm has initiated research coverage of City Windmills with a BUY recommendation.
Silvia Quandt & Cie, one of the most reputable German brokerage firms specializing in the fields of cleantech and new energies, has initiated coverage of the company. Silvia Quandt & Cie issued an internal note to its customers and a full research note on September 6th, 2011. This published 20-page research report has conducted an in-depth analysis of the business perspectives of City Windmills and comes to the conclusion that the company's share price is currently undervalued and could appreciate up to their 1.25 euros per share target price.
Clean Wind Energy Tower, Inc. (OTCBB:CWET), is presenting at the fifth annual Modern Energy Forum, held Sept. 13-15 at the Ritz-Carlton in Denver, Colo.
Ron Pickett, President & CEO of Clean Wind Energy Tower, Inc. stated: "We are honored to be presenting at the 2011 Modern Energy Forum and are looking forward to speaking with the attending investment professionals regarding the execution of our business model."
Wind Works Power Corp. (OTCQB:WWPW )(Frankfurt:R5E1.F - )(WKN: A0RPM2) announced today they have submitted a letter of intent with the North Dakota PSC to enter the permitting process for Thunder Spirit, a 150 megawatt (MW) wind energy project located in North Dakota.
Thunder Spirit recently emerged from a 5-year Midwest ISO (MISO) study process of 7,800 MW of North Dakota-Montana interconnection applications as the winning project with its unique attributes of both having almost no electric transmission system upgrade requirements and being located in one of the highest wind energy resource areas in MISO.
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Visit the CWET showcase page at Investorideas.com : http://www.investorideas.com/CO/CWE/
Visit the City Windmills showcase profile at Investorideas.com
http://www.investorideas.com/CO/CYW/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energystocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebookhttp://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.City Windmills is a paid showcase Frankfurt wind stock , 3500 per month plus 5000 shares.
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact:
800.665.0411
Point
City Windmills, Ltd. (Frankfurt : CYW.F, CYW.DE) announced today that Silvia Quandt & Cie, a leading German investment banking and brokerage firm has initiated research coverage of City Windmills with a BUY recommendation.
Silvia Quandt & Cie, one of the most reputable German brokerage firms specializing in the fields of cleantech and new energies, has initiated coverage of the company. Silvia Quandt & Cie issued an internal note to its customers and a full research note on September 6th, 2011. This published 20-page research report has conducted an in-depth analysis of the business perspectives of City Windmills and comes to the conclusion that the company's share price is currently undervalued and could appreciate up to their 1.25 euros per share target price.
Clean Wind Energy Tower, Inc. (OTCBB:CWET), is presenting at the fifth annual Modern Energy Forum, held Sept. 13-15 at the Ritz-Carlton in Denver, Colo.
Ron Pickett, President & CEO of Clean Wind Energy Tower, Inc. stated: "We are honored to be presenting at the 2011 Modern Energy Forum and are looking forward to speaking with the attending investment professionals regarding the execution of our business model."
Wind Works Power Corp. (OTCQB:WWPW )(Frankfurt:R5E1.F - )(WKN: A0RPM2) announced today they have submitted a letter of intent with the North Dakota PSC to enter the permitting process for Thunder Spirit, a 150 megawatt (MW) wind energy project located in North Dakota.
Thunder Spirit recently emerged from a 5-year Midwest ISO (MISO) study process of 7,800 MW of North Dakota-Montana interconnection applications as the winning project with its unique attributes of both having almost no electric transmission system upgrade requirements and being located in one of the highest wind energy resource areas in MISO.
Research more wind stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Visit the CWET showcase page at Investorideas.com : http://www.investorideas.com/CO/CWE/
Visit the City Windmills showcase profile at Investorideas.com
http://www.investorideas.com/CO/CYW/
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
Sign up at Investor Ideas for free investor alerts including news on wind stocks
http://www.investorideas.com/Resources/Newsletter.asp
Follow Investorideas.com on Twitterhttp://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebookhttp://www.facebook.com/Investorideas
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.City Windmills is a paid showcase Frankfurt wind stock , 3500 per month plus 5000 shares.
Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
For more information about Investorideas.com contact:
800.665.0411
City Windmills Ltd. (CYW.F) (CYW.DE) announces initiation of research coverage with a BUY recommendation by Silvia Quandt & Cie
MANCHESTER, U.K. - September 12, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces that Silvia Quandt & Cie, a leading German investment banking and brokerage firm has initiated research coverage of City Windmills with a BUY recommendation.
Silvia Quandt & Cie, one of the most reputable German brokerage firms specializing in the fields of cleantech and new energies, has initiated coverage of the company. Silvia Quandt & Cie issued an internal note to its customers and a full research note on September 6th, 2011. This published 20-page research report has conducted an in-depth analysis of the business perspectives of City Windmills and comes to the conclusion that the company's share price is currently undervalued and could appreciate up to their 1.25 euros per share target price.
"The reputation of Silvia Quandt & Cie as a top brokerage firm in the field of clean energy has been firmly established over the last several years." said Sean Kelly, CFO and founder of City Windmills Ltd. "Their forecasts on our business perspectives seem quite in line with our views on our initial business focus - servicing governmental entities by supplying them with clean, green wind energy" he added. "We are especially pleased that a firm with the stature of Sylvia Quandt & Cie is now actively following our company so early in our corporate evolution. We believe it is a strong testimony of our existing business plan and future potential. We look forward to developing our relationship with Sylvia Quandt & Cie and presenting to their large institutional following in the coming months."
The current research report of Silvia Quandt & Cie with an initial price target of 1.25 euros can be downloaded from the following link: http://www.citywindmills.com/ investors
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
MANCHESTER, U.K. - September 12, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces that Silvia Quandt & Cie, a leading German investment banking and brokerage firm has initiated research coverage of City Windmills with a BUY recommendation.
Silvia Quandt & Cie, one of the most reputable German brokerage firms specializing in the fields of cleantech and new energies, has initiated coverage of the company. Silvia Quandt & Cie issued an internal note to its customers and a full research note on September 6th, 2011. This published 20-page research report has conducted an in-depth analysis of the business perspectives of City Windmills and comes to the conclusion that the company's share price is currently undervalued and could appreciate up to their 1.25 euros per share target price.
"The reputation of Silvia Quandt & Cie as a top brokerage firm in the field of clean energy has been firmly established over the last several years." said Sean Kelly, CFO and founder of City Windmills Ltd. "Their forecasts on our business perspectives seem quite in line with our views on our initial business focus - servicing governmental entities by supplying them with clean, green wind energy" he added. "We are especially pleased that a firm with the stature of Sylvia Quandt & Cie is now actively following our company so early in our corporate evolution. We believe it is a strong testimony of our existing business plan and future potential. We look forward to developing our relationship with Sylvia Quandt & Cie and presenting to their large institutional following in the coming months."
The current research report of Silvia Quandt & Cie with an initial price target of 1.25 euros can be downloaded from the following link: http://www.citywindmills.com/ investors
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
City Wind Mills, Ltd.. (CYW.F) is a Frankfurt listed wind stock showcased on Investorideas.com and related green blogs
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
CFO and founder Sean Kelly (CYW.F, CYW.DE) Discusses Small Wind Turbine/ Green Outdoor Advertising Model
MANCHESTER, U.K. - September 12, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW.F, CYW.DE - www.citywindmills.com) announces that it has released today a management radio interview on the Boersen Radio Network (BRN). BRN specializes in highlighting high growth publicly traded companies to its listener base.
The interview by BRN was conducted by Sean Kelly, CFO and founder of City Windmills Ltd.: "We want to get the good word out to investors" he said. "Our windmills are in demand as buyers understand that now the door is open for producing energy for one's own consumption at prices competing against the grid prices" he added. "There is a tremendous opportunity ahead for City Windmills. As we move closer to full production, there has been a lot more interest in our company. We are happy to discuss our revolutionary technology that generates renewable energy through small wind while tapping into the lucrative global advertising market. We expect to be doing more interviews in the future as the word rapidly spreads through the investment community about City Windmills. We are committed to keeping our shareholders and interested followers updated on all our future progress."
The interview in German language and can be listened at the following link:
http://www.sbroker.de/sbl/mdaten_analyse/audio_boerse_detail?articleID=20400# .
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
MANCHESTER, U.K. - September 12, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW.F, CYW.DE - www.citywindmills.com) announces that it has released today a management radio interview on the Boersen Radio Network (BRN). BRN specializes in highlighting high growth publicly traded companies to its listener base.
The interview by BRN was conducted by Sean Kelly, CFO and founder of City Windmills Ltd.: "We want to get the good word out to investors" he said. "Our windmills are in demand as buyers understand that now the door is open for producing energy for one's own consumption at prices competing against the grid prices" he added. "There is a tremendous opportunity ahead for City Windmills. As we move closer to full production, there has been a lot more interest in our company. We are happy to discuss our revolutionary technology that generates renewable energy through small wind while tapping into the lucrative global advertising market. We expect to be doing more interviews in the future as the word rapidly spreads through the investment community about City Windmills. We are committed to keeping our shareholders and interested followers updated on all our future progress."
The interview in German language and can be listened at the following link:
http://www.sbroker.de/sbl/mdaten_analyse/audio_boerse_detail?articleID=20400# .
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
City Wind Mills, Ltd.. (CYW.F) is a Frankfurt listed wind stock showcased on Investorideas.com and related green blogs
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Friday's NASDAQ Top Gainers: SPEX, CBPO, GCOM, ULTA
POINTROBERTS - September 12, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Friday, September 09, 2011.
Spherix Incorporated (NASDAQ:SPEX) was the biggest gainerFriday,soaring $1.30 (96.30%) to close at $2.65 after it announced that its drug candidate, SPX-106, achieved statistically significant reductions in VLDL and LDL cholesterol when administered in combination with Dtagatose (SPX-106T) for nine weeks to genetically engineered mice prone to dyslipidemia.
The company is an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies.
China Biologic Products Inc (NASDAQ:CBPO) rose 1.24 (17.08%) to $14.71 after the company said that it earned 8 cents a share on revenue of $435.3 million in its third quarter, well ahead of analysts’ estimates of a loss of 8 cents a share on revenue of $443.25 million. For the current quarter, the company projects to generate revenue of $440 to $460 million.
Globecomm Systems, Inc. ( NASDAQ:GCOM) added 1.00 (8.39%) to $12.92 after it reported fiscal year 2011 revenue of $274.2 million, up 20 percent from a year ago and a company record. The services segment was nearly 70 percent of the total.
Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) moved8.69 (14.54%) to $68.45 after the company said that it earned 33 cents a share on revenue of $214.6 million in its first quarter, compared to analysts estimates of 33 cents a share on revenue of $198.15 million.
The company also projects to earn 30-36 cents a share on revenue of $192 to $210 million in its second quarter.
Investor Research Tools;
Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
800-665-0411
Source - Investorideas.com
POINT
Spherix Incorporated (NASDAQ:SPEX) was the biggest gainerFriday,soaring $1.30 (96.30%) to close at $2.65 after it announced that its drug candidate, SPX-106, achieved statistically significant reductions in VLDL and LDL cholesterol when administered in combination with Dtagatose (SPX-106T) for nine weeks to genetically engineered mice prone to dyslipidemia.
The company is an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies.
China Biologic Products Inc (NASDAQ:CBPO) rose 1.24 (17.08%) to $14.71 after the company said that it earned 8 cents a share on revenue of $435.3 million in its third quarter, well ahead of analysts’ estimates of a loss of 8 cents a share on revenue of $443.25 million. For the current quarter, the company projects to generate revenue of $440 to $460 million.
Globecomm Systems, Inc. ( NASDAQ:GCOM) added 1.00 (8.39%) to $12.92 after it reported fiscal year 2011 revenue of $274.2 million, up 20 percent from a year ago and a company record. The services segment was nearly 70 percent of the total.
Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) moved8.69 (14.54%) to $68.45 after the company said that it earned 33 cents a share on revenue of $214.6 million in its first quarter, compared to analysts estimates of 33 cents a share on revenue of $198.15 million.
The company also projects to earn 30-36 cents a share on revenue of $192 to $210 million in its second quarter.
Investor Research Tools;
Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks (over 1300 green stocks in directory) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
800-665-0411
Source - Investorideas.com
Friday's OTC Percentage Gainers: FIND, CDSI, EAPH, BBDA
FindEx.com, Inc. (OTC: FIND) was the biggest gainer soared 0.0033 (63.46%) to $0.0085 with more than 37K traded hands. The stock has jumped over 183% in the past week on increased volume. Recently, the stock had made a new 52-week high of $0.03.
CDSI Holdings Inc. (OTC:CDSI) surged 0.250 (62.50%) to close at new 52-week high of $0.650 on over 7.5K shares trading hands, compared to its average volume of 6.85K shares. CDSI Holdings Inc. is a shell company. The Company is focused on seeking new business opportunities. The Company was formed to develop an on-line service that transmits name, address, telephone number and other related information digitally to users of personal computers.
Easton Pharmaceuticals Inc (OTC: EAPH) added 0.0370 (132.14%) to $0.06520 on over 3.16 million shares - over 10X its average volume. Easton Pharmaceuticals Inc., formerly LAM Industries, Inc, develops; markets and licenses wound healing and transdermally delivered drugs, therapeutic preparations and cosmetics for the prescription, over-the-counter and cosmetic markets, using its L.A.M. Ionic Polymer Matrix technology (L.A.M. IPM).
Bebida Beverage Company (OTC: BBDA) climbed 0.0010 (40.00%) to $0.0035. Bebida Beverage Company is engaged in functional beverages. The Company's products include water, energy drinks and other functional drinks.
Investorideas.com Free Investor Tools;
Learn More about Investorideas.com showcase stocks
http://www.investorideas.com/Showcase/
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Become a Member
Research renewable energy stocks, gold stocks, water stocks, oil and gas and more with the largest stock directories online for investors
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only 13 stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Source - Investorideas.com
800-665-0411
Biotech and Pharma News; BioSante Pharmaceuticals (NASDAQ: BPAX) Successfully Completes LibiGel® Pharmacokinetic Study
LINCOLNSHIRE, Ill. - September 12, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free testosterone, bioavailable testosterone and total testosterone in the serum of postmenopausal women to within the normal ranges for younger, premenopausal women. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in postmenopausal women, for which there is no FDA-approved product.
The LibiGel PK study was conducted as part of the required studies to be submitted in the LibiGel new drug application (NDA), which is anticipated by the fourth quarter of 2012. The PK study was conducted in 24 postmenopausal subjects for a total of 63 days, in the absence of estrogen therapy, as well as in the same women when treated with a transdermal estradiol patch and subsequently oral estrogen. There were no differences in blood levels of testosterone regardless of the absence or presence of estrogen therapy, whether transdermal or oral.
The data from the PK study showed that testosterone blood levels were similar on days 14, 21, 42 and 63 of the study, indicating that there was no buildup of testosterone blood levels with daily LibiGel treatment. Additionally, free and bioavailable testosterone returned to baseline levels within 36-48 hours after the last dose of LibiGel, indicating effective elimination after dosing is discontinued. The testosterone blood levels produced in this study were very similar to those seen in the BioSante LibiGel Phase II efficacy trial reported previously, and they were very similar to blood levels observed in transdermal testosterone patch studies, which also demonstrated efficacy in the treatment of HSDD. Importantly, in the LibiGel PK study, there were no measurable increases in blood levels of the most active estrogen, estradiol, which could have occurred as a result of the conversion of testosterone to estradiol. BioSante plans to present the full PK study results at an upcoming medical meeting.
"Significantly, none of the subjects in the LibiGel PK study had average testosterone concentrations above the normal range for younger, premenopausal women, a finding that may be a key component in the safety evaluation of LibiGel by FDA," noted Michael C. Snabes, M.D., Ph.D., senior vice president of medical affairs at BioSante. "This finding adds to our confidence that the results of our ongoing, long-term safety study of LibiGel will be favorable."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The two on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have each enrolled over 500 surgically menopausal women for a six-month clinical trial. The efficacy trials, which completed enrollment in the first quarter 2011, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily, pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p <0.0001); this increase also was significant versus placebo (p <0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the UnitedStates , in surgically menopausal women distressed by their low sexual desire and activity.
In addition, BioSante is conducting a Phase III LibiGel safety study, which is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that completed enrollment of 3,656 women on June 2, 2011 and has accrued over 4,500 women-years of exposure. The safety study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
LINCOLNSHIRE, Ill. - September 12, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX), today announced successful completion of its principal LibiGel (testosterone gel) pharmacokinetic (PK) study. The top-line results indicate that LibiGel increases levels of free testosterone, bioavailable testosterone and total testosterone in the serum of postmenopausal women to within the normal ranges for younger, premenopausal women. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in postmenopausal women, for which there is no FDA-approved product.
The LibiGel PK study was conducted as part of the required studies to be submitted in the LibiGel new drug application (NDA), which is anticipated by the fourth quarter of 2012. The PK study was conducted in 24 postmenopausal subjects for a total of 63 days, in the absence of estrogen therapy, as well as in the same women when treated with a transdermal estradiol patch and subsequently oral estrogen. There were no differences in blood levels of testosterone regardless of the absence or presence of estrogen therapy, whether transdermal or oral.
The data from the PK study showed that testosterone blood levels were similar on days 14, 21, 42 and 63 of the study, indicating that there was no buildup of testosterone blood levels with daily LibiGel treatment. Additionally, free and bioavailable testosterone returned to baseline levels within 36-48 hours after the last dose of LibiGel, indicating effective elimination after dosing is discontinued. The testosterone blood levels produced in this study were very similar to those seen in the BioSante LibiGel Phase II efficacy trial reported previously, and they were very similar to blood levels observed in transdermal testosterone patch studies, which also demonstrated efficacy in the treatment of HSDD. Importantly, in the LibiGel PK study, there were no measurable increases in blood levels of the most active estrogen, estradiol, which could have occurred as a result of the conversion of testosterone to estradiol. BioSante plans to present the full PK study results at an upcoming medical meeting.
"Significantly, none of the subjects in the LibiGel PK study had average testosterone concentrations above the normal range for younger, premenopausal women, a finding that may be a key component in the safety evaluation of LibiGel by FDA," noted Michael C. Snabes, M.D., Ph.D., senior vice president of medical affairs at BioSante. "This finding adds to our confidence that the results of our ongoing, long-term safety study of LibiGel will be favorable."
About LibiGel®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The two on-going Phase III efficacy trials are double-blind, placebo-controlled trials that have each enrolled over 500 surgically menopausal women for a six-month clinical trial. The efficacy trials, which completed enrollment in the first quarter 2011, are being conducted under an FDA-approved special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily, pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from HSDD by 238 percent versus baseline (p <0.0001); this increase also was significant versus placebo (p <0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United
In addition, BioSante is conducting a Phase III LibiGel safety study, which is a randomized, double-blind, placebo-controlled, multi-center, cardiovascular (CV) events and breast cancer study that completed enrollment of 3,656 women on June 2, 2011 and has accrued over 4,500 women-years of exposure. The safety study will continue for a total of five years, however, BioSante will use the safety study data as part of an NDA submission after the last subject enrolled has completed 12 months of exposure to LibiGel or placebo.
The LibiGel safety study is tracking a predefined list of CV events, in agreement with the FDA, including CV death, myocardial infarction and stroke in women 50 years of age or older and suffering from at least two CV risk factors including hypertension and diabetes. The objective of the safety study is to show the relative safety of testosterone compared to placebo in the number of CV events. The incidence of breast cancer also is being tracked over the course of the study. The study represents the largest data base of the safety of testosterone in women.
Upon completion of the statistical analyses of the safety study and efficacy trials, BioSante intends to submit an NDA to the FDA, requesting approval to market LibiGel for the treatment of HSDD in menopausal women. The NDA submission is targeted for the fourth quarter of 2012.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "continue," "could," "believe," "intends," "continue," "expects," "anticipates," "estimates," "may," other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com
Friday, September 09, 2011
City Windmills Ltd. (CYW.F) (CYW.DE) Agreement calls for 10,000 City Windmills XLT Wind Turbines
MANCHESTER, U.K. - September 9, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces that it has signed a significant long-term non-exclusive business agreement with a major governmental organization, which opens the door to 10,000 windmills to be manufactured and delivered.
Sean Kelly, CFO and founder of City Windmills US Inc. said, "Government organizations are starting to well understand the need for new clean energy for their own consumption, rendering them independent from oil. This first agreement opens the door to potential sales of 80,000,000 euros over the next 18 months."
The agreement signed by City Windmills calls for 10,000 of City Windmills XLT wind turbines to be delivered and installed to governmental customers on several continents.
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
MANCHESTER, U.K. - September 9, 2011 (Investorideas.com renewable energy/green newswire) - City Windmills, Ltd. (Frankfurt symbol: CYW, CYW.DE) - www.citywindmills.com), announces that it has signed a significant long-term non-exclusive business agreement with a major governmental organization, which opens the door to 10,000 windmills to be manufactured and delivered.
Sean Kelly, CFO and founder of City Windmills US Inc. said, "Government organizations are starting to well understand the need for new clean energy for their own consumption, rendering them independent from oil. This first agreement opens the door to potential sales of 80,000,000 euros over the next 18 months."
The agreement signed by City Windmills calls for 10,000 of City Windmills XLT wind turbines to be delivered and installed to governmental customers on several continents.
City Windmills Ltd. is a windmill company seeking to transform the dominant paradigm of energy production and consumption around the globe, by integrating the three notions of powerful energy production from wind, proximity to the end user and advertisement of brands and products.
This press release may contain 'forward-looking statements.' Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan.
CONTACT:
Peter Kazimirski, CEO, +41 79 663 5234, peter.kazimirski@citywindmills.com
Sean Kelly, CFO, +41 79 203 7124, sean.kelly@citywindmills.com
City Wind Mills, Ltd.. (CYW.F) is a Frankfurt listed wind stock showcased on Investorideas.com and related green blogs
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Visit the showcase profile for City Wind Mills, Ltd.. (CYW.F) to learn more
Request new, articles and trading alerts on City Wind Mills, Ltd.. (CYW.F)
Disclosure: City Wind Mills, Ltd. (CYW.F) is a paid advertising online client ( 6 months � thirty five hundred per month , five thousand shares)
Biotech Investor Stock News Alert; BioSante (NASDAQ: BPAX) Trading its Way Back to $3.00
Point Roberts, WA, LINCOLNSHIRE, Ill –September 9, 2011,– Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for the week of September 9th.
The stock has bounced back as high as $2.82 in today’s trading, and was up 9.9% yesterday at $2.89.
In recent commentary on Motley Fool,3 Biotechs Ready to Move, the author noted, "Despite the future risks, though, there's no doubt BioSante will rise on positive efficacy data. With a market cap under $300 million, there are very little sales baked into the price."
News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences
“LINCOLNSHIRE, Ill. - September 1, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that BioSante will present at three healthcare conferences in September. The three presentations are as follows: on Wednesday, September 7, 2011 at 9:45 am EDT at the Stifel Nicolaus Healthcare Conference in Boston; on Monday, September 12, 2011 at 1:35 pm EDT at the Rodman & Renshaw Healthcare Conference in New York; and on September 27, 2011 at 2:00 pm EDT at the JMP Securities Healthcare Conference in New York.
BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.
A live audio webcast of remarks by Phillip Donenberg, senior vice president & CFO of BioSante, at the Stifel Nicolaus Conference may be accessed at http://www.veracast.com/webcasts/stifel/healthcare 2011/ 07104418.cfm: the webcast will be archived for 30 days. A live audio webcast of remarks by Stephen M. Simes, president & CEO of BioSante, at the Rodman Conference may be accessed at http://www.wsw.com/webcast/ rrshq20/bpax: the webcast will be archived for 90 days. A live audio webcast of Mr. Simes’ remarks at the JMP Conference can be accessed at http://www.wsw.com/webcast/ jmp14/bpa/: the webcast will be archived for 90 days.”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/09011.asp
Contact BioSante:
For info about BioSante Pharmaceuticals, Inc
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
Point Roberts, WA, LINCOLNSHIRE, Ill –September 9, 2011,– Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for the week of September 9th.
The stock has bounced back as high as $2.82 in today’s trading, and was up 9.9% yesterday at $2.89.
In recent commentary on Motley Fool,3 Biotechs Ready to Move, the author noted, "Despite the future risks, though, there's no doubt BioSante will rise on positive efficacy data. With a market cap under $300 million, there are very little sales baked into the price."
News Excerpt: Pharma News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Three September Healthcare Conferences
“LINCOLNSHIRE, Ill. - September 1, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced that BioSante will present at three healthcare conferences in September. The three presentations are as follows: on Wednesday, September 7, 2011 at 9:45 am EDT at the Stifel Nicolaus Healthcare Conference in Boston; on Monday, September 12, 2011 at 1:35 pm EDT at the Rodman & Renshaw Healthcare Conference in New York; and on September 27, 2011 at 2:00 pm EDT at the JMP Securities Healthcare Conference in New York.
BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.
A live audio webcast of remarks by Phillip Donenberg, senior vice president & CFO of BioSante, at the Stifel Nicolaus Conference may be accessed at http://www.veracast.com/webcasts/stifel/healthcare 2011/ 07104418.cfm: the webcast will be archived for 30 days. A live audio webcast of remarks by Stephen M. Simes, president & CEO of BioSante, at the Rodman Conference may be accessed at http://www.wsw.com/webcast/ rrshq20/bpax: the webcast will be archived for 90 days. A live audio webcast of Mr. Simes’ remarks at the JMP Conference can be accessed at http://www.wsw.com/webcast/ jmp14/bpa/: the webcast will be archived for 90 days.”
Full News at: http://www.investorideas.com/CO/BPAX/news/2011/09011.asp
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology. Additional information is available online at: www.biosantepharma.com.
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as “will,” “continue,” “could,” “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact BioSante:
For info about BioSante Pharmaceuticals, Inc
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com
800 665 0411 cvanzant@investorideas.com
Friday's Electric Car Stocks Trading; ABAT, AONE, (OTC: EVCA), TSLA
PointRoberts WA - September 9, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, reports on electric car stocks following recent news from the DOE that it will 'Promote Electric Vehicles in 24 States and Train a Workforce for Advanced Vehicle Development'.
Overall markets are down in this morning's trading session, passed on to cleantech stocks, but not reflective of the sector, creating a buying opportunity for long term investors.
EV /Green Trading Snapshot
"By developing the next generation of automotive engineers and preparing communities for plug-in electric vehicles, these projects will help reduce our nation's dependence on oil imports, create jobs, and help America capture the growing global market for advanced vehicles," said Secretary Chu.
Projects to support community planning for plug-in electric vehicles and charging infrastructure will receive $8.5 million through DOE's Clean Cities initiative to facilitate local public-private partnerships that will develop EV deployment strategies. The funding recipients range from communities with extensive EV planning experience to those that are eager to begin, but have not previously had the resources to do so. These one-year projects will help communities address their specific needs, which include updating permitting processes, revising codes, training municipal personnel, promoting public awareness, or developing incentives, and each will create a plan that will be publicly available so that other stakeholders can learn best practices.
To view a map of the award locations and read the full list of Clean Cities' award winners see below .Source: www.energy.gov
Electric Car/ Green Car Company Snapshot
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energystocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Point
Overall markets are down in this morning's trading session, passed on to cleantech stocks, but not reflective of the sector, creating a buying opportunity for long term investors.
EV /Green Trading Snapshot
- A123 Systems, Inc. (NasdaqGM: AONE) trading at $4.68, down 0.15 (3.11%) 10:21AM EDT
- Advanced Battery Technologies, (NasdaqCM: ABAT ) trading at 1.30, down 0.0050 (0.38%) 10:18AM EDT
- ENER1, Inc. (NASDAQ: HEV) trading up at 0.3811, up 0.0111 (3.00%) 10:21AM EDT
- Ecotality, Inc. (NasdaqCM: ECTY) trading up at 2.32, up 0.01 (0.43%)
- EVCARCO (OTCBB: EVCA)) trading at 0.0039., down 0.0004 (9.30%)
- Tesla Motors, Inc. (NASDAQ: TSLA) trading at 23.46, down 0.15 (0.64%) 10:25AM EDT
"By developing the next generation of automotive engineers and preparing communities for plug-in electric vehicles, these projects will help reduce our nation's dependence on oil imports, create jobs, and help America capture the growing global market for advanced vehicles," said Secretary Chu.
Projects to support community planning for plug-in electric vehicles and charging infrastructure will receive $8.5 million through DOE's Clean Cities initiative to facilitate local public-private partnerships that will develop EV deployment strategies. The funding recipients range from communities with extensive EV planning experience to those that are eager to begin, but have not previously had the resources to do so. These one-year projects will help communities address their specific needs, which include updating permitting processes, revising codes, training municipal personnel, promoting public awareness, or developing incentives, and each will create a plan that will be publicly available so that other stakeholders can learn best practices.
To view a map of the award locations and read the full list of Clean Cities' award winners see below .Source: www.energy.gov
Electric Car/ Green Car Company Snapshot
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
Visit the EVCA profile at Investorideas.com - http://www.investorideas.com/CO/EVCA/
Research electric car stocks and green auto stocks, lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
About Investorideas.com - a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/ or
www.renewableenergystocks.com
Thursday's NASDAQ Top Gainers: CALP, PMIC, TNGO, BSDM
POINT ROBERTS - September 9, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for September 08, 2011.
Caliper Life Sciences Inc. (NASDAQ:CALP) was the biggest gaineron Nasdaq jumping $3.04 (41.14%) to close at $10.43 ,making a new 52-week high of $10.48 after the company was agreed to be acquired by PerkinElmer, Inc. (NYSE: PKI) for $600 million. The $10.50-per-share buyout price represents a 42% premium over Caliper's closing price Wednesday.
Caliper Life Sciences' portfolio includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions
Penn Millers Holding Corporation (NASDAQ:PMIC) rose 3.83 (23.50%) to $20.13 and made a new 52-week high of $20.25 after the subsidiary of ACE Limited (NYSE: ACE) agreed to buy the company for $20.50 a share in cash.
Tangoe Inc (NASDAQ:TNGO) added 2.00 (17.46%) to $13.45 and made a new 52-week high of $14.11. The stock has climbed over 23% in the past one week on increasing volume and showing good technical sign. So far this year, the stock is up over 15%.
BSD Medical Corporation (NASDAQ:BSDM) surged 0.41 (14.96%) to $3.15 on no major news. However, the stock is still down over 32% so far this year. The stock has a 52-week range of $2.22-$7.40.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks ( over 1300 green stocks in directory ) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Source - Investorideas.com 800-665-0411
POINT ROBERTS - September 9, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for September 08, 2011.
Caliper Life Sciences Inc. (NASDAQ:CALP) was the biggest gaineron Nasdaq jumping $3.04 (41.14%) to close at $10.43 ,making a new 52-week high of $10.48 after the company was agreed to be acquired by PerkinElmer, Inc. (NYSE: PKI) for $600 million. The $10.50-per-share buyout price represents a 42% premium over Caliper's closing price Wednesday.
Caliper Life Sciences' portfolio includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions
Penn Millers Holding Corporation (NASDAQ:PMIC) rose 3.83 (23.50%) to $20.13 and made a new 52-week high of $20.25 after the subsidiary of ACE Limited (NYSE: ACE) agreed to buy the company for $20.50 a share in cash.
Tangoe Inc (NASDAQ:TNGO) added 2.00 (17.46%) to $13.45 and made a new 52-week high of $14.11. The stock has climbed over 23% in the past one week on increasing volume and showing good technical sign. So far this year, the stock is up over 15%.
BSD Medical Corporation (NASDAQ:BSDM) surged 0.41 (14.96%) to $3.15 on no major news. However, the stock is still down over 32% so far this year. The stock has a 52-week range of $2.22-$7.40.
Investor Research Tools;
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 13 of the best stock directories online;
Research oil and gas stocks, gold stocks, water stocks, renewable energy stocks ( over 1300 green stocks in directory ) and more
Join: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Source - Investorideas.com 800-665-0411
Subscribe to:
Posts (Atom)